

# Effects of mapping algorithms on gene selection for RNA-Seq analysis: pulmonary response to acute neonatal hyperoxia

Chin-Yi Chu, Soumyaroop Bhattacharya, Zhongyang Zhou, Min Yee, Ashley Lopez, Valerie A Lunger, Bradley Buczynski, Michael O'Reilly, Thomas Mariani

**Background:** A major goal of RNA-Seq data analysis is to reconstruct the full set of gene transcripts expressed in a biological sample in order to quantify their expression levels. The process typically involves multiple steps including mapping short sequence reads to a reference genome, and estimating expression levels based on these mappings. Multiple algorithms and approaches for each processing step exist, and the impact of different methods on estimation of gene expression is not entirely clear.

**Methods:** We evaluated the impact of three common mapping algorithms on differential expression analysis in an RNA-Seq dataset describing the lung response to acute neonatal hyperoxia. RNA-Seq data generated using the Illumina platform were mapped and aligned using CASAVA, TopHat, and SHRiMP against the mouse genome. Significance Analysis of Microarrays and Cuffdiff were used to identify differentially expressed genes between hyperoxia-challenged and age matched control mice.

**Results:** 1403 genes were detected as differentially expressed by least one mapping and gene selection method. A majority of genes (>65%) were identified by all three mapping methods, regardless of the gene selection approach. Expression patterns for 52 genes were examined by quantitative polymerase chain reaction (qPCR). Importantly, we found different validation rates for genes selected by each method; 72% for CASAVA, 69% for TopHat and 63% for SHRiMP. Surprisingly, the validation rate for genes selected by all three mapping methods was no greater than the best single method.

**Conclusion:** The choice of mapping strategy impacts the reliability of gene selection for RNA-Seq data analysis.

2 Effects of Mapping Algorithms on Gene Selection for RNA-Seq Analysis: Pulmonary Response to  
3 Acute Neonatal Hyperoxia.

4  
5 Chin-Yi Chu<sup>1,2,a</sup>, Soumyaroop Bhattacharya<sup>1,2,a</sup>, Zhongyang Zhou<sup>1</sup>, Min Yee<sup>1</sup>, Ashley M Lopez<sup>1</sup>,  
6 Valerie A Lunger<sup>1</sup>, Bradley W Buczynski<sup>1</sup>, Michael A O'Reilly<sup>1,3</sup>, Thomas J Mariani<sup>1,2</sup>

7  
8 <sup>a</sup>These authors contributed equally.

9  
10 <sup>1</sup>Division of Neonatology, <sup>2</sup>Pediatric Molecular and Personalized Medicine (PMPM) Program, and  
11 <sup>3</sup>Perinatal and Pediatric Origins of Disease (PPOD) Program, Department of Pediatrics, University of  
12 Rochester Medical Center, Rochester NY, United States of America

13  
14 3 Figures

15 5 Tables

16 4 Supplemental Figures

17 1 Supplemental Table

18  
19 Author Emails:

20 Chin-Yi Chu: [chinyi\\_chu@urmc.rochester.edu](mailto:chinyi_chu@urmc.rochester.edu)

21 Soumyaroop Bhattacharya: [soumyaroop\\_bhattacharya@urmc.rochester.edu](mailto:soumyaroop_bhattacharya@urmc.rochester.edu)

22 Zhongyang Zhou: [zzhou10@ur.rochester.edu](mailto:zzhou10@ur.rochester.edu)

23 Min Yee: [min\\_yee@urmc.rochester.edu](mailto:min_yee@urmc.rochester.edu)

24 Ashley M Lopez: [ashley\\_lopez@urmc.rochester.edu](mailto:ashley_lopez@urmc.rochester.edu)

25 Valerie A Lunger: [valerie\\_lunger@urmc.rochester.edu](mailto:valerie_lunger@urmc.rochester.edu)

26 Bradley W Buczynski: [bradley.buczynski@wilresearch.com](mailto:bradley.buczynski@wilresearch.com)

27 Michael A O'Reilly: [michael\\_oreilly@urmc.rochester.edu](mailto:michael_oreilly@urmc.rochester.edu)

28 Thomas J Mariani: [tom\\_mariani@urmc.rochester.edu](mailto:tom_mariani@urmc.rochester.edu)

29  
30 Address for Correspondence:

31  
32 Thomas J Mariani, PhD

33 Division of Neonatology and

34 Center for Pediatric Biomedical Research

35 University of Rochester Medical Center,

36 601 Elmwood Ave, Box 850,

37 Rochester, NY 14642, USA

38  
39 Phone: 585-276-4616

40 Fax: 585-276-2643

41 Email: [Tom\\_Mariani@URMC.rochester.edu](mailto:Tom_Mariani@URMC.rochester.edu)

42  
43 Running Title: Comparative mapping of RNA-Seq

44 Keywords: TopHat, SHRiMP, CASAVA, qPCR

45 Supported by: HL67392, HL091968, HHSN272201200005C

46 ABSTRACT

47 **Background:** A major goal of RNA-Seq data analysis is to reconstruct the full set of gene transcripts  
48 expressed in a biological sample in order to quantify their expression levels. The process typically  
49 involves multiple steps including mapping short sequence reads to a reference genome, and estimating  
50 expression levels based on these mappings. Multiple algorithms and approaches for each processing  
51 step exist, and the impact of different methods on estimation of gene expression is not entirely clear.

52  
53 **Methods:** We evaluated the impact of three common mapping algorithms on differential expression  
54 analysis in an RNA-Seq dataset describing the lung response to acute neonatal hyperoxia. RNA-Seq  
55 data generated using the Illumina platform were mapped and aligned using CASAVA, TopHat, and  
56 SHRiMP against the mouse genome. Significance Analysis of Microarrays and Cuffdiff were used to  
57 identify differentially expressed genes between hyperoxia-challenged and age matched control mice.

58  
59 **Results:** 1403 genes were detected as differentially expressed by least one mapping and gene selection  
60 method. A majority of genes (>65%) were identified by all three mapping methods, regardless of the  
61 gene selection approach. Expression patterns for 52 genes were examined by quantitative polymerase  
62 chain reaction (qPCR). Importantly, we found different validation rates for genes selected by each  
63 method; 72% for CASAVA, 69% for TopHat and 63% for SHRiMP. Surprisingly, the validation rate  
64 for genes selected by all three mapping methods was no greater than the best single method.

65  
66 **Conclusion:** The choice of mapping strategy impacts the reliability of gene selection for RNA-Seq  
67 data analysis.

## 68 INTRODUCTION

69 Genome-wide expression profiling is used to assess the expression of thousands of genes  
70 simultaneously, with the ultimate goal of creating a comprehensive description of expression at the  
71 mRNA level. Historically DNA microarray technology has been used to measure genome-wide  
72 expression. With the advent of next-generation sequencing, high-throughput sequence-based  
73 approaches for expression analysis are becoming an increasingly popular alternative to microarrays.  
74 RNA-Seq, otherwise known as Whole Transcriptome Shotgun Sequencing (WTSS), refers to the use of  
75 high-throughput technologies to sequence cDNA in order to get information about a sample's RNA  
76 content. Applications of RNA-Seq may include analyzing the genome for coding and non-coding RNA  
77 [1]. RNA-Seq has been used in studies of transcription in yeast [2], Arabidopsis [3], mouse [4, 5], and  
78 human [6, 7]. RNA-Seq is a promising replacement for microarrays as initial studies have shown that  
79 RNA-Seq expression estimates are highly reproducible[6] and are often more accurate, based on  
80 assessments by either quantitative PCR (qPCR) or spike-in experiments [2, 5]. The primary advantages  
81 of RNA-Seq are its large dynamic range (spanning five orders of magnitude), low background noise,  
82 reduced input sample (RNA) requirement and ability to detect novel transcripts, when studied at  
83 appropriate coverage depth [8]. However, similar to the early days of microarray analysis, there are still  
84 a number of experimental and computational issues remaining to be resolved for RNA-Seq.

85  
86 The process of RNA-Seq involves four major steps: (i) generation of cDNA libraries from the RNA  
87 samples, (ii) generating millions of short sequence “reads” from these cDNA libraries (that are  
88 proportional to the mRNA diversity of the initial RNA sample), (iii) mapping the sequence reads to a  
89 reference genome, and (iv) summarizing the mapped reads into raw expression level measures, for  
90 subsequent normalization and analysis. Methods and computational tools are being rapidly developed  
91 to meet the challenges of these steps. Presently, more than 60 mappers are available to accomplish this  
92 task [9, 10]. Our choices of mappers represent a spliced (TopHat) and a contemporary unspliced  
93 (SHRiMP) freeware aligner, as well as the vendor recommended default aligner. While both CASAVA  
94 and TopHat are spliced read aligner which is a critical feature when aligning RNA-seq reads to a  
95 reference genome, we chose to compare them with SHRiMP, which is an unspliced read aligner[11].  
96 Consensus Assessment of Sequence And Variation, (CASAVA) is the part of Illumina's sequencing  
97 analysis software that performs alignment of a sequencing run to a reference genome and subsequent  
98 variant analysis and read counting [12]. Its underlying alignment algorithm is ELAND (Efficient  
99 Large-Scale Alignment of Nucleotide Databases). ELAND is very fast and can perform multi-seed and  
100 gapped alignment. TopHat is a fast and popular spliced aligner for RNA-Seq reads [13]. It aligns RNA-  
101 Seq reads to mammalian-sized genomes by using its underlying mapping engine, either Bowtie or  
102 Bowtie2. TopHat consists of three mapping steps: transcriptome mapping, genome mapping, and  
103 spliced mapping. This three-step pipeline assures the best and unique alignment for each read. It can  
104 identify novel splice sites with direct mapping to known transcripts, producing sensitive and accurate  
105 alignments, even for highly repetitive genomes or in the presence of pseudogenes. Short Read Mapping  
106 Program (SHRiMP) is an unspliced aligner and it aligns reads against a target genome using an  
107 algorithm distinct from that TopHat uses [14]. It was initially developed with the multitudinous short  
108 reads of next generation sequencers and Applied Biosystem's colorspace genomic representation. The  
109 algorithm can align reads with extensive polymorphism and sequencing errors. It can also perform the  
110 multi-seed alignment to speed up the alignment.

111  
112 Here we studied the biological impact of these three mapping algorithms on identification of  
113 differentially expressed genes in a typical experimental model dataset. We included molecular  
114 validation for genes identified in individually mapped datasets as a means of determining the estimated

115 reliability of each method. Similar studies in the past have used empirical and simulated datasets [15-  
116 18], however, these studies did not have further validation results.

117

118

119 METHODS

120 *RNA-Seq Data*

121 This data set represents high throughput sequencing of seven cDNA libraries generated from whole  
122 lung tissue RNA recovered from mice treated under hyperoxic conditions in the newborn period (n=3)  
123 or age-matched controls (n=4). Mice were exposed to 100% oxygen, 40-70% humidity between birth  
124 and postnatal day 10 as shown previously [19]. Mice were housed in sterile microisolator cages in a  
125 specified pathogen-free environment and exposed to super-physiological levels of oxygen according to  
126 a protocol (Protocol No. 2007-121R) approved by the University Committee on Animal Resources at  
127 the University of Rochester. The University Committee on Animal Resources (UCAR) at the  
128 University of Rochester reviewed and approved these studies. The data were generated on the Illumina  
129 Genome Analyzer II platform at an average sequence depth of 20 million reads (65 bases in length) per  
130 sample as reported previously [20].

131  
132 *Short-Read Alignment*

133 Sequences were mapped to the mouse genome (mm10), containing 21,718 unique genes, using  
134 multiple alignment algorithms. CASAVA (v 1.7) pipeline software was implemented with the  
135 manufacturer default settings, using the ELAND aligner program in Multiplexer setting, for separating  
136 bar-coded reads into different bins. Tophat (v 2.0.9) was implemented using Bowtie (v 2.1.0) and  
137 SAMtools (v 0.1.18) with default parameters (b2-sensitive, report-secondary-alignments, library-type  
138 fr-unstranded). SHRiMP (v 2.2.3) was implemented using SAMtools (v 0.1.18) with default  
139 parameters (gmapper -ls -qv-offset 33 single\_en\_reads-). For TopHat and SHRiMP mapping, HTSeq  
140 (v 0.5.3p3) was used to generate the count matrices with the following parameters: 'htseq-count -m  
141 intersection-strict -s no'. For both SHRiMP and TopHat alignments, mouse gene annotation file (GTF)  
142 for mouse genome build 10 obtained from UCSC was used for alignment. Codes for mapping and  
143 generating the raw counts are available in shown in Supplemental Table 1.

144  
145 *Normalization*

146 Alignment counts obtained from CASAVA, SHRiMP and TopHat were further normalized using reads  
147 per million bases (RPM) or trimmed-mean (TM), independently. RPM normalization involves dividing  
148 the raw count for each individual gene in a particular sample by the sum total of counts for all the  
149 genes in that sample (Equation 1). It is a modification of the RPKM (reads per kilobase transcript per  
150 million reads) approach, excluding normalization for transcript length [5].

151  
152 
$$Count_{RPM} = \frac{Count_{Raw}}{\sum_{sampleA} Count} \dots(1)$$
  
153  
154  
155

156 TM normalization involves calculation of the mean of 5th-95th percentile of raw counts for each  
157 sample, which is used to determine a sample-specific normalization factor. The raw counts for all  
158 genes for a sample are then multiplied by this factor (Equation 2).

159  
160 
$$Count_{TrimMEAN} = Count_{Raw} \left( \frac{1}{\mu_{Trim(5-95\%)}} \right) \dots(2)$$
  
161

162 *Gene Selection*

163 Genes that were not detected in all samples of at least one experimental group (hyperoxia-treated or  
164 control) were excluded from analysis. Multiple gene selection approaches were applied on each  
165 normalized and filtered dataset, from each of the three mapping algorithms. The filtered and  
166 normalized data, were however not log-transformed. Significance Analysis for Microarrays (SAM) is a

167 frequentist approach used for identification of differentially expressed genes that uses a modified t-  
168 statistic with permutations [21]. SAM was applied using the minimum median False Discovery Rate  
169 (FDR) possible, in MultiExperiment Viewer (MeV) v4.8.1 (<http://www.tm4.org/mev.html>). For the  
170 purposes of this study, SAM threshold of median FDR of 0 was applied. Cuffdiff uses the Cufflinks  
171 transcript quantification to calculate gene expression levels in different conditions, and tests them for  
172 significant differences [22]. It uses FPKM (fragments per kilobase of exon per million fragments  
173 mapped) normalization. Cuffdiff was applied using mouse gene annotation file (GTF) for mouse  
174 genome build 10 obtained from UCSC with a significance threshold of FDR adjusted  $q < 0.05$ .

175

#### 176 *Molecular Validation*

177 cDNA were synthesised from RNA samples isolated from individual lungs using the iScript Reverse  
178 Transcription Kit (BioRad, Hercules, CA). qPCR was performed on a Viia7 (Applied Biosystems,  
179 Santa Clara, CA) using SYBR green chemistry as previously described [23]. Gene-specific assays  
180 primer sequences were retrieved from the MGH Primer Bank (<http://pga.mgh.harvard.edu/primerbank>).  
181 Gene expression levels (dCt) were calculated relative to the measured Ct value of PPIA (peptidyl  
182 prolyl isomerase A or cyclophilin A) as an internal, endogenous control and were analyzed for relative  
183 expression changes by the ddCt method as previously described [23]. QPCR data were assessed using  
184 both the students T-test and the Mann-Whitney U test at a  $p < 0.05$ .



## 185 RESULTS

186 The main objective here is to compare the effect of different, state-of-the-art alignment and mapping  
187 procedures upon the accuracy of gene selection. The data set we used for this analysis consists of 3  
188 experimental treatment samples (separate pools of RNA isolated from lungs of neonatal mice  
189 challenged with hyperoxia) and 4 matched, normoxic controls [20]. As indicated in Figure 1, in order  
190 to complete the analysis, Fastq files were independently mapped using 3 different alignment methods;  
191 CASAVA, TopHat and SHRiMP. The mapped data were normalized and filtered, using tools  
192 appropriate for the mapping methods, and analyzed for differential expression using Significance  
193 Analysis for Microarrays (SAM) or Cuffdiff. In particular, we used reads per million (RPM) or  
194 trimmed mean (TM) normalization for SAM, and “fragments per kilobase of exon per million  
195 fragments mapped” (FPKM) normalization for Cuffdiff. Differential expression was estimated using  
196 SAM, for all three mapping methods, or Cuffdiff for TopHat and SHRiMP mapping. qPCR was used to  
197 assess the reliability of differential expression estimation.

198

### 199 *Mapping Statistics*

200 For each mapping algorithm we calculated the total number of reads, percentage of genes detected,  
201 alignment rate, number of aligned reads, and the number of reads assigned to genes. Table 1 shows a  
202 summary of these mapping statistics. SHRiMP gave highest total number of reads followed by those of  
203 CASAVA and TopHat. On an average, SHRiMP gave highest percent genes, detected (80%) which  
204 was slightly above those of CASAVA (77%) and TopHat (76%). In addition, the total number of reads  
205 assigned to mapped genes was highest in SHRiMP ( $12.75 \times 10^6$ ), followed by TopHat ( $12.56 \times 10^6$ )  
206 and CASAVA ( $11.18 \times 10^6$ ).

207

208 The correlation analysis confirmed strong general concordance on the gene expression measurements  
209 across mappers. Pearson correlation coefficients between the raw or either of normalized counts  
210 generated by the TopHat and CASAVA was found to be well above 0.8 indicating the data were of  
211 comparable quality (Figure 1). While the pearson correlation coefficients between the raw or either of  
212 normalized counts generated by the SHRiMP and CASAVA were found to be 0.46 or more, the  
213 correlation coefficients between the raw or either of normalized counts generated by the SHRiMP and  
214 TopHat were 0.58 or more. Figure 2 shows representative plots (from one control and one hyperoxia  
215 sample) for same-sample correlations among the normalized counts obtained using three mappers.  
216 Correlation plots for raw and both normalized counts can be seen in Supplemental Figure 1.

217

### 218 *CASAVA (v 1.7)*

219 On average, expression of 77% of the genes in the genome was detected in the samples using  
220 CASAVA. After removing signal from genes not present in all samples of at least one experimental  
221 group, the expression of 16,079 genes were assessed for differential expression (Table 2). As described  
222 elsewhere [20] SAM identified 1020 genes in the TM-normalized data and 813 genes in the RPM-  
223 normalized data. A total of 798 genes were common, and 300 of these had a fold-change greater than  
224 or equal to 2. There were a greater number of genes showing significant decreases in expression in  
225 response to treatment (56%) than were increased.

226

### 227 *SHRiMP (v 2.2.3)*

228 On average, expression of 80% of the genes in the genome was detected in the lung tissue samples  
229 using SHRiMP. After removing signal from genes not present in all samples of at least one  
230 experimental group, the expression of 17,814 genes were assessed for differential expression (Table 3).  
231 SAM identified 879 genes in the TM-normalized data and 937 genes in the RPM-normalized data. A



232 total of 857 genes were common, and 386 of these had a fold-change greater than or equal to 2. Similar  
233 to CASAVA mapped data, there were more genes showing significant decreases in expression in  
234 response to treatment (60%) than were increased. Cuffdiff identified 3886 genes as differentially  
235 expressed, and 1087 of those had a magnitude of change greater than or equal to 2. In addition to  
236 selecting a greater number of genes as significantly affected, Cuffdiff identified a greater number of  
237 genes showing significant increases in expression in response to treatment (57%) than were decreased.

#### 238 239 *TopHat (v 2.0.9)*

240 On average, expression of 76% of the genes in the genome was detected in the lung tissue samples  
241 using TopHat. After removing signal from genes not present in all samples of at least one experimental  
242 group, the expression of 16,892 genes were assessed for differential expression (Table 4). SAM  
243 identified 880 genes in the TM-normalized data and 951 genes in the RPM-normalized data. A total of  
244 860 genes were common, and 396 of these had a fold-change greater than or equal to 2. Cuffdiff  
245 identified 2831 genes as differentially expressed, and 1044 of those had a fold-change greater than or  
246 equal to 2. Again (similar to SHRiMP mapped data) Cuffdiff identified a greater number of genes  
247 showing significant increases in expression in response to treatment (57%) than were decreased.

#### 248 249 *Consistency of Gene Selection*

250 We tested the consistency of individual gene selection tools. SAM identified 699 genes that were  
251 selected as differentially expressed by all three mapping methods, of which 251 had a fold change  
252 greater than or equal to 2 (Supplemental Figure 2). CASAVA tended to be more conservative in the  
253 number of genes identified, with a substantial majority of these genes also selected by SHRiMP and  
254 TopHat.

255  
256 Cuffdiff identified 2719 genes that were selected as differentially expressed using both SHRiMP and  
257 TopHat, of which 919 had a fold change greater than or equal to 2 (Supplemental Figure 3). Again,  
258 there was a high degree of consistency between SHRiMP and TopHat, with nearly 90% of genes  
259 identified using data mapped by both methods.

260  
261 There were a total of 240 genes identified by all these analyses (Supplemental Figure 4). SAM,  
262 implemented as described, was much more highly conservative in gene selection. Most genes identified  
263 by SAM were also identified by Cuffdiff, while a majority of genes identified by Cuffdiff (74%) were  
264 not identified by SAM.

265  
266 In order to compare gene selection estimation with other mapping algorithms (TopHat and SHRiMP),  
267 we subsequently, focused on Cuffdiff as well. A total of 267 genes were identified as differentially  
268 expressed by SAM on CASAVA, and by Cuffdiff on both SHRiMP and TopHat, which had a fold  
269 change greater than or equal to 2 (Figure 3).

#### 270 271 *Molecular Validation*

272 Predicted changes were evaluated by qPCR for 52 of the genes (Table 5). Out of these 32 genes were  
273 identified using CASAVA mapped data separately as reported previously [20]. We chose 10 additional  
274 genes each that were uniquely selected by SHRiMP or TopHat for qPCR validation. These genes were  
275 chosen based on prior knowledge of their relevance to oxidative stress response or lung biology in  
276 general. Genes, that had a significant difference between the two groups (hyperoxia and controls) by  
277 either t-test or Mann-Whitney U test at p-value less than 0.05, were designated as successfully  
278 validated. We report detailed qPCR results for 32 genes identified using CASAVA mapped data

279 separately [20]. We validated differential expression for 23 of 32 (72%) of these genes selected by  
280 CASAVA. Of these 32 genes, 29 were selected as differentially expressed by TopHat, and 20 of those  
281 genes (69%) showed significant differences in expression by qPCR. Of these 32 genes, 28 were  
282 selected as differentially expressed by SHRiMP, and 19 of those genes (63%) showed significant  
283 differences in expression by qPCR. Of these 32 genes, 27 were selected as differentially expressed by  
284 all three mapping methods, and 18 of those genes (67%) showed significant differences in expression  
285 by qPCR.

286  
287 Two of the 32 genes were uniquely selected by CASAVA, and both of those genes (100%) showed  
288 significant differences in expression by qPCR. For TopHat, 7 of the 10 (70%) additional unique genes,  
289 and a total of 27 of 39 (69%) genes tested showed significant differences in expression by qPCR. For  
290 SHRiMP, 5 of the 10 (50%) additional unique genes, and a total of 24 of 38 (63%) genes tested showed  
291 significant differences in expression by qPCR.

292 DISCUSSION

293 RNA-Seq is becoming the method of choice for genome-wide transcriptomics analysis, and has been  
294 used to identify post-transcriptional changes and other modifications in human diseases such as cancer  
295 [24]. Many methods for data processing and analysis are available, but the best approaches to estimate  
296 differential expression for specific types of data sets are not at all clear. Here, we describe an empirical  
297 assessment of the impact three different mapping algorithms upon the reliability of differential  
298 expression estimation, in a typical genome-wide expression data set from an animal model of disease.  
299 Our initial analysis of this data set indicated a substantial gene expression response associated with the  
300 experimental challenge, such that it was appropriate for the current studies. The rationale behind  
301 choosing these three included multiple factors, such as manufacturer recommendation, usage among  
302 research community, cost, efficiency and ease of usage, among others.

303  
304 Researchers can consider multiple mapping algorithms in their RNA-Seq analysis, which brings up  
305 issues of interoperability. To achieve interoperability, input and output formats need to be  
306 standardized. Currently the level of interoperability is high since most of the mapping algorithms  
307 accept FASTQ format input files and generate SAM/BAM files as output. Prior publications  
308 comparing various combinations of mapping algorithms and tests for differential gene expression have  
309 found high level of consistency among the results [15, 16]. However, these prior studies did not include  
310 subsequent attempts of molecular validation, which is a critical step in any differential expression  
311 analysis.

312  
313 It is important to point out that, of the three different mapping algorithms compared in this study, two  
314 of them (SHRiMP and TopHat) were developed at academic institutions, and are freely available,  
315 while the third (CASAVA) is commercial software that is provided by the manufacturer of the  
316 sequencing instrument. We observed that SHRiMP mapping resulted in higher rates of genes detected  
317 as expressed in the samples (80% for SHRiMP, 77% for CASAVA and 76% for TopHat), when  
318 compared to either CASAVA or TopHat. This is likely due to the fact that SHRiMP allows reads to be  
319 mapped to multiple loci, unlike TopHat and CASAVA, which require reads are mapped to a single  
320 locus. Interestingly, a higher number of genes detected as expressed led to higher estimation of  
321 differential expression for SHRiMP, but a somewhat lower level of accuracy as defined by qPCR.

322  
323 We report here only a subset of the possible permutations of analysis that could be completed with the  
324 mapping, normalization and gene selection methods we have included. In addition to comparing the  
325 mappers, we also looked at the effects of methods of count generation by running correlation analysis  
326 among the raw and normalized counts of the same samples, and found that even among methods using  
327 different count generation approaches (CASAVA and TopHat), there was a high level of correlation  
328 among the counts (Supplemental Figure 1). This indicated to us that the counting methods, independent  
329 of mapping algorithm, may not have a big impact. Our analysis also revealed that there was a high  
330 level of consistency among the two normalization methods (RPM and TM) on each mapped version of  
331 data, when it comes to gene selection, irrespective of the test for differential expression used. We,  
332 however did notice higher number of genes being identified by Cuffdiff when using FPKM normalized  
333 counts. Even though SAM appeared to be effective in the current data set, applying this analytical  
334 approach to other RNA-Seq datasets identified a number of limitations. For this, and other reasons  
335 (e.g., free access to software, difficulties in generating bam files from CASAVA), we decided to use  
336 SAM analysis of CASAVA data as our benchmark, and focus on the efficiency of Cuffdiff selection  
337 using SHRiMP and TopHat mapping.

338

339 Encouragingly, we find that all mapping approaches performed similarly. Overall validation rates for  
340 estimation of differential expression were comparable. CASAVA was most conservative with gene  
341 selection, consistently estimating fewer genes as differentially expressed as compared to SHRiMP and  
342 TopHat. However, this was associated with a higher frequency of validation; 72% for all genes, 100%  
343 for unique genes. Conversely, SHRiMP tended to be slightly more liberal than TopHat, but had a  
344 reduced validation rate than the other mapping approaches (63% for all genes, 50% for unique genes).  
345 It is likely that this is at least partially due to its tolerance for including non-unique mapping for  
346 individual reads. Interestingly, TopHat selected genes as differentially expressed at nearly the same  
347 rate as SHRiMP, but its validation rate was much closer to that of CASAVA (69% for all genes, 70%  
348 for unique genes). It is significant to note that individual genes selected by all mapping methods did  
349 not demonstrate a higher validation rate than those identified by a single mapping method alone.

## 350 351 CONCLUSIONS

352 In summary, these data describe the differences that can be expected in the performance of these three  
353 common mapping strategies, when applied to a typical genome-wide expression data set comparing  
354 biological paradigms, such as an animal- or cell model response. Our data highlight the importance of  
355 considering the analytical goals when choosing a data analysis approach. For instance, focused  
356 analyses may want to consider a more conservative approach with a slightly higher validation rate,  
357 while discovery approaches may be more tolerant to, and benefit from, more liberal approaches with a  
358 slightly lower validation rate.

359 ACKNOWLEDGMENTS

360 We would like to thank University of Rochester Center for Integrated Research Computing (CIRC) for  
361 providing computational resources. We would also like to thank University of Rochester Medical  
362 Center Genomics Research Center (GRC) for their support and Stephen L. Welle, Ph.D. for his  
363 guidance and suggestions in preparation of the manuscript.

364

365 COMPETING INTERESTS

366 The authors declare that they have no competing interests.

367

368 AUTHOR CONTRIBUTIONS

369 CC carried out the sequence alignment, differential expression analysis, and drafted the manuscript. SB  
370 carried out the differential expression analysis and drafted the manuscript. ZZ carried out qPCR  
371 validation. AML, VAL participated in cDNA synthesis and qPCR. MY, BWB participated in  
372 generating the animal data. MAO conceived of the study, and participated in its design. TJM conceived  
373 of the study, participated in its design and coordination and helped to draft the manuscript. All authors  
374 read and approved the final manuscript.

375

## 376 REFERENCES

- 377 1. Ingolia NT, Brar GA, Rouskin S, McGeachy AM, Weissman JS: **The ribosome profiling**  
378 **strategy for monitoring translation in vivo by deep sequencing of ribosome-protected**  
379 **mRNA fragments.** *Nature protocols* 2012, **7(8):1534-1550.**
- 380 2. Nagalakshmi U, Wang Z, Waern K, Shou C, Raha D, Gerstein M, Snyder M: **The**  
381 **transcriptional landscape of the yeast genome defined by RNA sequencing.** *Science* 2008,  
382 **320(5881):1344-1349.**
- 383 3. Lister R, O'Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH, Ecker JR: **Highly**  
384 **integrated single-base resolution maps of the epigenome in Arabidopsis.** *Cell* 2008,  
385 **133(3):523-536.**
- 386 4. Cloonan N, Grimmond SM: **Transcriptome content and dynamics at single-nucleotide**  
387 **resolution.** *Genome biology* 2008, **9(9):234.**
- 388 5. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: **Mapping and quantifying**  
389 **mammalian transcriptomes by RNA-Seq.** *Nature methods* 2008, **5(7):621-628.**
- 390 6. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y: **RNA-seq: an assessment of**  
391 **technical reproducibility and comparison with gene expression arrays.** *Genome research*  
392 2008, **18(9):1509-1517.**
- 393 7. Morin R, Bainbridge M, Fejes A, Hirst M, Krzywinski M, Pugh T, McDonald H, Varhol R,  
394 Jones S, Marra M: **Profiling the HeLa S3 transcriptome using randomly primed cDNA and**  
395 **massively parallel short-read sequencing.** *BioTechniques* 2008, **45(1):81-94.**
- 396 8. Wang Z, Gerstein M, Snyder M: **RNA-Seq: a revolutionary tool for transcriptomics.** *Nature*  
397 *reviews Genetics* 2009, **10(1):57-63.**
- 398 9. Fonseca NA, Rung J, Brazma A, Marioni JC: **Tools for mapping high-throughput**  
399 **sequencing data.** *Bioinformatics* 2012, **28(24):3169-3177.**
- 400 10. Lindner R, Friedel CC: **A comprehensive evaluation of alignment algorithms in the context**  
401 **of RNA-seq.** *PLoS one* 2012, **7(12):e52403.**
- 402 11. Garber M, Grabherr MG, Guttman M, Trapnell C: **Computational methods for**  
403 **transcriptome annotation and quantification using RNA-seq.** *Nature methods* 2011,  
404 **8(6):469-477.**
- 405 12. Gambera D, Carta S, Crainz E, Fortina M, Maniscalco P, Ferrata P: **Metallosis due to**  
406 **impingement between the socket and the femoral head in a total hip prosthesis. A case**  
407 **report.** *Acta bio-medica : Atenei Parmensis* 2002, **73(5-6):85-91.**
- 408 13. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL: **TopHat2: accurate**  
409 **alignment of transcriptomes in the presence of insertions, deletions and gene fusions.**  
410 *Genome biology* 2013, **14(4):R36.**
- 411 14. David M, Dzamba M, Lister D, Ilie L, Brudno M: **SHRiMP2: sensitive yet practical SHort**  
412 **Read Mapping.** *Bioinformatics* 2011, **27(7):1011-1012.**
- 413 15. Nookaew I, Papini M, Pornputtpong N, Scalcinati G, Fagerberg L, Uhlen M, Nielsen J: **A**  
414 **comprehensive comparison of RNA-Seq-based transcriptome analysis from reads to**  
415 **differential gene expression and cross-comparison with microarrays: a case study in**  
416 **Saccharomyces cerevisiae.** *Nucleic acids research* 2012, **40(20):10084-10097.**
- 417 16. Sonesson C, Delorenzi M: **A comparison of methods for differential expression analysis of**  
418 **RNA-seq data.** *BMC bioinformatics* 2013, **14:91.**
- 419 17. Benjamin AM, Nichols M, Burke TW, Ginsburg GS, Lucas JE: **Comparing reference-based**  
420 **RNA-Seq mapping methods for non-human primate data.** *BMC genomics* 2014, **15(1):570.**

- 421 18. Zhang ZH, Jhaveri DJ, Marshall VM, Bauer DC, Edson J, Narayanan RK, Robinson GJ,  
422 Lundberg AE, Bartlett PF, Wray NR *et al*: **A Comparative Study of Techniques for**  
423 **Differential Expression Analysis on RNA-Seq Data.** *PloS one* 2014, **9**(8):e103207.
- 424 19. Yee M, Vitiello PF, Roper JM, Staversky RJ, Wright TW, McGrath-Morrow SA, Maniscalco  
425 WM, Finkelstein JN, O'Reilly MA: **Type II epithelial cells are critical target for hyperoxia-**  
426 **mediated impairment of postnatal lung development.** *American journal of physiology Lung*  
427 *cellular and molecular physiology* 2006, **291**(5):L1101-1111.
- 428 20. Bhattacharya S, Zhou Z, Yee M, Chu CY, Lopez AM, Lunger VA, Solleti SK, Resseguie E,  
429 Buczynski B, Mariani TJ *et al*: **The genome-wide transcriptional response to neonatal**  
430 **hyperoxia identifies Ahr as a key regulator.** *American journal of physiology Lung cellular*  
431 *and molecular physiology* 2014, **307**(7):L516-523.
- 432 21. Tusher VG, Tibshirani R, Chu G: **Significance analysis of microarrays applied to the**  
433 **ionizing radiation response.** *Proceedings of the National Academy of Sciences of the United*  
434 *States of America* 2001, **98**(9):5116-5121.
- 435 22. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L: **Differential analysis**  
436 **of gene regulation at transcript resolution with RNA-seq.** *Nature biotechnology* 2013,  
437 **31**(1):46-53.
- 438 23. Bhattacharya S, Go D, Krenitsky DL, Huyck HL, Solleti SK, Lunger VA, Metlay L, Srisuma S,  
439 Wert SE, Mariani TJ *et al*: **Genome-wide transcriptional profiling reveals connective tissue**  
440 **mast cell accumulation in bronchopulmonary dysplasia.** *American journal of respiratory*  
441 *and critical care medicine* 2012, **186**(4):349-358.
- 442 24. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T,  
443 Palanisamy N, Chinnaiyan AM: **Transcriptome sequencing to detect gene fusions in cancer.**  
444 *Nature* 2009, **458**(7234):97-101.
- 445  
446



447 Figure 1: Analysis Workflow. RNA-Seq raw reads were mapped using three separate methods;  
448 CASAVA, SHRiMP and TopHat. Mapped data were normalized using RPM or TM for all three  
449 mapping methods, or FPKM for SHRiMP and TopHat only. Normalized data were filtered and tested  
450 for differential expression using either SAM for all three mapping methods, or CuffDiff for SHRiMP  
451 and TopHat. A subset of the differentially expressed genes was assessed by qPCR.

452

453 Figure 2: Correlation between mapped reads of the sample across three mappers. RPM normalized  
454 counts from individual mappers for the same sample were plotted to identify the correlation between  
455 the expression levels. Shown here are dot plots of two samples (Control: RA 11+12 and Hyperoxia: O2  
456 11+12) between TopHat and CASAVA counts (A:Control, D:Hyperoxia), SHRiMP and CASAVA  
457 (B:Control, E:Hyperoxia) and TopHat and SHRiMP (C:Control, F:Hyperoxia).

458

459 Figure 3: Summary of gene selection comparison. A comparison of genes with a fold-change greater  
460 than or equal to 2 identified as differentially expressed by SAM using CASAVA mapped data, and by  
461 Cuffdiff on SHRiMP and TopHat mapped data.

462 Table 1: Summary of mapping statistics.

463

	CASAVA	SHRiMP	TopHat
No of genes in genome	21718	23278	23278
Median number of genes mapped	16731	18674	17789
Median number of raw reads (x 10 <sup>6</sup> )	16.53	16.53	16.53
Median number of reads assigned to genes (x 10 <sup>6</sup> )	11.18	12.75	12.56
Median alignment rate (%)	NA	85.26	74.94
Median gene detection rate (%)	77.03	80.21	76.42

464

465 Table 2: Differential expression estimated by CASAVA.

466

CASAVA	SAM		
	RPM	TM	Overlap
Significant Genes	1017	1019	798
FC > 2	472	446	300
No. of up-regulated	210	180	132
No. of down-regulated	262	266	168
<i>% of up-regulated</i>	<i>0.44</i>	<i>0.40</i>	<i>0.44</i>
<i>% of down-regulated</i>	<i>0.56</i>	<i>0.60</i>	<i>0.56</i>

467

468 Table 3: Differential expression estimation by SHRiMP.

469

SHRiMP	SAM			Cuffdiff
	RPM	TM	Overlap	FPKM
Significant Gene	937	879	857	3886
FC > 2	401	386	379	1087
No. of up-regulated	170	157	153	623
No. of down-regulated	231	229	226	464
<i>% of up-regulated</i>	<i>0.42</i>	<i>0.41</i>	<i>0.40</i>	<i>0.57</i>
<i>% of down-regulated</i>	<i>0.58</i>	<i>0.59</i>	<i>0.60</i>	<i>0.43</i>

470

471

472 Table 4: Differential expression estimation by TopHat.

473

TopHat	SAM			Cuffdiff
	RPM	TM	Overlap	FPKM
Significant Gene	951	880	860	2831
FC > 2	418	412	396	1044
No. of up-regulated	179	172	165	593
No. of down-regulated	239	240	231	451
<i>% of up-regulated</i>	<i>0.43</i>	<i>0.42</i>	<i>0.42</i>	<i>0.57</i>
<i>% of down-regulated</i>	<i>0.57</i>	<i>0.58</i>	<i>0.58</i>	<i>0.43</i>

474

475 Table 5: qPCR validation rate. Genes were significantly different by either T-Test or MWU at  $p < 0.05$

476


Mapping Programs	No. of Gene Chosen	No. of Gene Validated	Validation Rate (%)	Validation Rate of Unique Gene (%)
CASAVA	32	23	71.87%	100%
TopHat	39	27	69.23%	70%
SHRIMP	38	24	63.16%	50%
Overlap	27	18	66.67%	

477

## Figure 1 (on next page)

### Analysis Workflow.

RNA-Seq raw reads were mapped using three separate methods; CASAVA, SHRiMP and TopHat. Mapped data were normalized using RPM or TM for all three mapping methods, or FPKM for SHRiMP and TopHat only. Normalized data were filtered and tested for differential expression using either SAM for all three mapping methods, or CuffDiff for SHRiMP and TopHat. A subset of the differentially expressed genes was assessed by qPCR.






## Figure 2 (on next page)




Correlation between mapped reads of the sample across three mappers.

RPM normalized counts from individual mappers for the same sample were plotted to identify the correlation between the expression levels. Shown here are dot plots of two samples (Control: RA 11+12 and Hyperoxia: O2 11+12) between TopHat and CASAVA counts (A:Control, D:Hyperoxia), SHRiMP and CASAVA (B:Control, E:Hyperoxia) and TopHat and SHRiMP (C:Control, F:Hyperoxia). @0

# Control



# Hyperoxia





### **Figure 3**(on next page)

Summary of gene selection comparison.

A comparison of genes with a fold-change greater than or equal to 2 identified as differentially expressed by SAM using CASAVA mapped data, and by Cuffdiff on SHRiMP and TopHat mapped data.

# SHRiMP

CuffDiff ( $q < 0.05$ )

FC > 2

PeerJ PrePrints

167

1

652

267

17

110

15

# CASAVA

SAM (FDR=0)

FC > 2

# TopHat

CuffDiff ( $q < 0.05$ )

FC > 2